BioSpace News Archive

Stealth BioTherapeutics Corp (Nasdaq: MITO), today announced that two abstracts have been selected for virtual presentations including a poster presentation and a late breaking research oral presentation at the upcoming 13th International Conference on Cachexia,

Kewaunee Scientific CorporationKewaunee Scientific Corporation reported results for its second quarter of fiscal year 2021, ended October 31, 2020.

BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced the results of an analysis of presence of target bacteria, Fusobacterium nucleatum, in tumor samples obtained from patients with colorectal cancer and reported on progress in engineering of genetic payloads for therapeutic applications.

The American Society for Reproductive Medicine’s newly launched Center for Policy and Leadership has released a groundbreaking new report, targeted to federal policymakers, entitled, Reproductive Health Care: A National Priority that Cannot Wait.

ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT

Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com (“Liberty” or the “Company”), a provider of high-quality cannabis, today announced it has hired Darrin Potter as Vice President of Operations

Oncternal Therapeutics, Inc. announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 16,666,667 shares of common stock of the Company, at a price to the public of $4.50 per share, less underwriting discounts and commissions.

Evaxion Biotech A/S, a clinical-stage AI-immunology company developing immunotherapies to improve the lives of patients with cancer and infectious diseases, announced the publication of an article in Nature Communications showing how deep data on immune complex stability could optimize immunotherapy in cancer.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that the Company’s Board of Directors has approved a first-quarter 2021 dividend of $0.17 per share.

Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators, a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce an oversubscribed $8 million financing.